Product Search for novus: Novus Biologicals

Novus Biologicals products are now on bio-techne.com

Sort By:

Products (3)

page of 1

3 Results for "novus"

AF886

Survivin Antibody [Unconjugated]

(2 Reviews)

(97 Publications)

100 μg

AF886

Western blot shows lysates of MCF-7 human breast cancer cell line and Jurkat human acute T cell leukemia cell line. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Survivin at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4.

Survivin was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Survivin was detected in immersion fixed paraffin-embedded sections of human prostate cancer tissue using 10 µg/mL Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) overnight at 4 °C. Before incubation with the primary antibody tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained with the Anti-Rabbit HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS005) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Simple Western lane view shows lysates of Jurkat human acute T cell leukemia cell line and MCF‑7 human breast cancer cell line, loaded at 0.2 mg/mL. A specific band was detected for Survivin at approximately 23 kDa (as indicated) using 5 µg/mL of Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein. B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C and D: Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed and -translated (IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma and cartilage lysates. For A, B and E the polyclonal rabbit anti-survivin antibody AF886 was used. For C and D the monoclonal mouse anti-survivin antibody clone 32.1 was used. Original magnifications: 200× (A and C) and 400× (B and D) and 600× (E). Image collected and cropped by CiteAb from the following open publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin is required for the proliferation of trophoblastic cells and depletion induces a G2/M arrest.(A) Cell viability assay. JAR (left panel), BeWo (middle panel) and HTR-8/SVneo (HTR, right panel) cells were non-treated (con), treated with either control scrambled siRNA (si con) or siRNA targeting survivin (si survivin) and cell viability was analyzed at indicated time points. Bar: ± SD. (B) Cell cycle profiles. Cells were depleted of survivin for 48 h and cell cycle analysis was performed. con: untreated cells as control. si con: treated with control scrambled siRNA. si survivin: treated with siRNA against survivin. Right panels: quantification of the sub-phases of the cell cycle. (C) Western blot analysis. BeWo cells were transfected with scrambled siRNA (si con) or siRNA targeting survivin (si survivin) for 24 h or 48 h and cellular extracts were prepared for Western blot analysis using indicated antibodies. beta -actin served as loading control. con: non-treated lysates as control. (D) Relative caspase-3/7 activity. The lysates from JAR or BeWo cells treated as in (C) were used for evaluating caspase-3/7 activity. The results are presented as mean ± SD. Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0073337), licensed under a CC-BY license. Not internally tested by R&D Systems.

ATM and DNA-PKCS induce cell cycle arrest after Survivin-RNAi. a: Western blot analysis of HCT116 and HCT116shATM total cell lysates following Survivin-RNAi (shSurv). Included are shLuc-transduced cells as control. Red values indicate densitometric estimation of protein levels, normalized to Tubulin. b: Indirect immunofluorescence analysis of transduced SBC-2 cells showing colocalisation of activated ATM (ATM S1981) and activated DNA-PK kinase (DNA-PKCS T2609) in shSurv polyploid cells. c: Western blot of HCT116 and HCT116p53−/− cell lysates showing analysis of p53 phosphorylation sites after Survivin knockdown. d: Proposed outline of Survivin RNAi phenotype and the observed DNA-damage response signaling. e: Analysis of HCT116 and HCT116shATM cells transduced with shSurv and combined treatment with DNA-PKCS inhibitor (DNA-PK-I, 10 μM Nu7026) or DMSO. Note combined inhibition of ATM and DNA-PKcs results in a decreased accumulation of p53 and p21waf/cip protein levels and reduction of gamma H2AX levels. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24886358), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin in tubulointerstitial cells.A, Western blot analysis of survivin protein in the renal cortex of wild type and Itga8-/- mice after induction of unilateral ureter obstruction (UUO). B,Exemplary photomicrographs show renal localization of survivin. Itga8+/+, wild type mice; Itga8-/-, Itga8-deficient mice. Data are means±SEM. # p<0.05 UUO versus control (co). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26938996), licensed under a CC-BY license. Not internally tested by R&D Systems.

Inhibition of PI3K gamma attenuates tumor growth in xenograft models associated with infiltrated macrophages.a Experimental procedure illustrating the TG100-115 treatment regimen in BALB/c mice. b CT26 cells (5 × 105 cells/mouse) were subcutaneously injected into the flanks of 6-week-old mice. Mean tumor volume of subcutaneously implanted vehicle- or TG100-115-treated mice (n = 5) and representative images of subcutaneous tumors at day 16 after treatment with vehicle or TG100-115 (box) are shown. c FACS analysis and quantification of CD11b+ F4/80+ (TAM) cell populations in CT26 tumors at day 14 posttreatment (n = 5) and expression levels of MHCII (M1) and CD206 (M2) in CD11b+ F4/80+ cell populations. d Graph showing the percentage of each population (M1, M2) in the vehicle-treated group in comparison with the TG100-115-treated group. e mRNA expression levels of genes involved in the proinflammatory response (il-1 beta , cxcl10) and antiinflammatory response (il-10 and tgf-beta ) were evaluated by real-time PCR in vehicle and TG100-155-treated groups. f Representative western blot analysis showing survival/EMT-related protein expression as well as ERK/AKT-FBW7-MCL-1 signal axis regulation in vehicle- and TG100-155-treated mouse tumor tissues. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

Opposite effects of M1 and M2 macrophages on tumor growth.a Tumor images and b tumor growth 3 weeks after transplantation of HCT116 cells after long-term coculture with differentiated M0, M1, or M2 macrophages (see Materials and Methods). Tumor size was measured 2–3 times a week with a caliper. Tumor volume was calculated using the following formula: tumor volume = (short length × long length × width)/2. The expression of SURVIVIN or p21c) and proliferation markers d in mouse subcutaneous tissues was evaluated by real-time PCR and western blotting, respectively. e Ki67 staining (1:200) of mouse subcutaneous tissues three weeks after subcutaneous injection. Scale bar: 100 μm. The results shown are presented as the mean ± SD from three mice per group. Actin was used as a loading control. *P < 0.05; **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin in tubulointerstitial cells.A, Western blot analysis of survivin protein in the renal cortex of wild type and Itga8-/- mice after induction of unilateral ureter obstruction (UUO). B,Exemplary photomicrographs show renal localization of survivin. Itga8+/+, wild type mice; Itga8-/-, Itga8-deficient mice. Data are means±SEM. # p<0.05 UUO versus control (co). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26938996), licensed under a CC-BY license. Not internally tested by R&D Systems.

Role of PI3K gamma in TAM-mediated colon cancer cell viability and EMT characteristics.mRNA expression levels of genes involved in the proinflammatory response (IL-1 alpha , IL-1 beta , CXCL10, and IL-8) and antiinflammatory response (IL-10 and CCL17) were evaluated by real-time PCR in M1 a and M2 b macrophages with or without treatment with 10 nm TG100-115 (PI3K gamma inhibitor) for 18 h. c HT29 cells were exposed to TG100-115-treated macrophage CM for 24 h. Cell viability was then measured by WST-1 assay. d Expression levels of apoptosis- and EMT-related markers in CM-treated HT29 cells. CMs were derived from TG100-115 (10 nm)-treated or untreated M0, M1, and M2 macrophages. HT29 cells e and PDCs f were incubated with TG100-115-treated macrophage CM for 24 h. Protein levels of MCL-1 and FBW7 were evaluated using western blotting. Actin was used as a loading control. The results are presented as the mean ± SE. *P < 0.05; **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

Analysis for RNA-induced silencing complex cleavage products in treated tumors and immunoblot analysis for target protein complexes and death signals in primary tumors. (A) Total RNA was isolated from tumor tissue and used for 5′ ligation-mediated RACE to determine whether RNA-induced silencing complex (RISC)-mediated cleavage of the transcript occurred. The predicted RACE products are indicated to the right, the size (base pairs (bp)) of the DNA standards shown on the left, and the treatment administered indicated above the lanes. (B) Immunoblot analysis of MDA-MB-231 day 10 tumor lysates following intravenous treatments of 0.01 mg/kg TBG-siCDK11, TBG-siCK2, or TBG-siCON1 as indicated above the blots. The signals for three mice per group are shown and the proteins detected are indicated on the right side of the blots. Actin signal was used as the loading control. (C) The protein signals from all mice in each treatment group were quantitated by densitometry using ImageJ software (National Institutes of Health Bethesda, MD, USA). Data presented as mean ± standard error. *P <0.05, **P <0.01. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TBG, tenfibgen. Image collected and cropped by CiteAb from the following open publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0524-0), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein. B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C and D: Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed and -translated (IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma and cartilage lysates. For A, B and E the polyclonal rabbit anti-survivin antibody AF886 was used. For C and D the monoclonal mouse anti-survivin antibody clone 32.1 was used. Original magnifications: 200× (A and C) and 400× (B and D) and 600× (E). Image collected and cropped by CiteAb from the following open publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Not internally tested by R&D Systems.

Ex vivo analysis of the role of macrophage CM in colon cancer patient-derived cells (PDCs).a Estimation of PDC viability after coculture with macrophage CM for 24 h using the WST-1 assay. Error bars are derived from three independent experiments. b Expression levels of apoptosis and EMT markers in macrophage CM-treated PDCs were measured by western blotting. c Wound-healing ability was evaluated by creating wounds on a confluent monolayer of PDCs using 1-Dish 35-mm-high culture inserts. d Activation of AKT and ERK and expression levels of MCL-1 and FBW7 assessed by western blotting. Actin was used as a loading control. The results are presented as the mean ± SE. **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

$Response over time to TBG-RNAi-CK2 treatment in PC3-LN4 xenograft tumors(A) Verification of nuclear and cytosol protein fractionation from tumor tissue is shown by comparative immunoblot analysis of CK2 alpha alpha ′, lamin A/C, ERp72, and actin. T1, T2, and T3 labels indicate different tumors. Antibody sourcing information is listed in Materials and Methods. (B) Immunoblot analysis of fractionated PC3-LN4 tumor lysates following intravenous treatments of 0.01 mg/kg TBG-RNAi-CK2 or TBG-RNAi-F7 as indicated above the blots. The signals for three mice per group are shown, the proteins detected are indicated on the right, and the cell fraction and size markers are indicated on the left. Actin signal was used as the loading control. T1, T2, and T3 labels indicate different tumors within each treatment group. Antibody sourcing information is listed in Materials and Methods. (C) The percentage of Ki-67-positive tumor cells was determined from Ki-67-stained tumor sections. The percentage of Ki-67-positive cells on each day was expressed relative to day 5 (setting day 5 as 100%) and is shown graphically for each treatment. Mean and standard deviation are shown. Sample sizes: n = 6 for all groups except n = 7 for TBG-RNAi-F7 day 7. Image collected and cropped by CiteAb from the following open publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11442), licensed under a CC-BY license. Not internally tested by R&D Systems.$

Immunoblot analyses following small interfering RNA-mediated downregulation of CDK11 and CK2 in breast cancer cells. Immunoblot analysis of MDA-MB-231 and SUM-149 cell lysates following small interfering RNA (siRNA) transfection. Transfected siRNAs are indicated above the blots, proteins detected are indicated on the right side of the blots. CDK11p110, cyclin L1 alpha , cyclin L2 alpha , and CK2 alpha alpha ′ beta lysates are 72 hours post transfection; caspase 3, Bcl-xL, and survivin lysates are 96 hours post transfection. Actin signal was used as the loading control. CDK, cyclin-dependent kinase; CK2, casein kinase 2. Image collected and cropped by CiteAb from the following open publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0524-0), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein. B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C and D: Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed and -translated (IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma and cartilage lysates. For A, B and E the polyclonal rabbit anti-survivin antibody AF886 was used. For C and D the monoclonal mouse anti-survivin antibody clone 32.1 was used. Original magnifications: 200× (A and C) and 400× (B and D) and 600× (E). Image collected and cropped by CiteAb from the following open publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, ,

Applications: , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF886-SP

compare

(select up to 3 products from this page to compare)

MAB886

Survivin Antibody (91630)

(7 Publications)

100 μg

MAB886

Human peripheral blood mononuclear cells were labeled with Human Survivin Monoclonal Antibody (Catalog # MAB886, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with PFA and permeabilized with saponin.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

,

Applications: ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	IC886U-100UG
Alexa Fluor 405	IC886V-100UG
Alexa Fluor 488	IC886G-100UG
Alexa Fluor 532	FAB886X
Alexa Fluor 594	IC886T-100UG
Alexa Fluor 647	IC886R-100UG
Alexa Fluor 700	IC886N-100UG
Alexa Fluor 750	IC886S-100UG
Allophycocyanin	FAB886A
Biotin	FAB886B
DyLight 350	FAB886D
DyLight 405	FAB886E
DyLight 488	FAB886K
DyLight 550	FAB886L
DyLight 594	FAB886M
DyLight 650	FAB886W
DyLight 680	FAB886Y
DyLight 755	FAB886Z
HRP	FAB886H
Janelia Fluor 549	FAB886I
Janelia Fluor 646	FAB886J
PerCP	FAB886C
Phycoerythrin	IC6472P
mFluor Violet 450 SE	FAB886MFV450
mFluor Violet 500 SE	FAB886MFV500
mFluor Violet 610 SE	FAB886MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	IC6472P
Carrier Free	MAB886-SP
Carrier Free	IC886V-100UG
Carrier Free	IC886G-100UG
Carrier Free	IC886U-100UG
Carrier Free	IC886T-100UG
Carrier Free	IC886S-100UG
Carrier Free	IC886R-100UG
Carrier Free	IC886N-100UG

compare

(select up to 3 products from this page to compare)

AF6471

Survivin Antibody [Unconjugated]

(3 Publications)

100 μg

AF6471

Survivin was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6471) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Western blot shows lysates of MCF-7 human breast cancer cell line and Jurkat human acute T cell leukemia cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6471) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for Survivin at approximately 18 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Simple Western lane view shows lysates of Jurkat human acute T cell leukemia cell line, loaded at 0.2 mg/mL. A specific band was detected for Survivin at approximately 24 kDa (as indicated) using 10 µg/mL of Goat Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6471) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the12-230 kDa separation system.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , , ,

Applications: , , , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Biotin	BAF6471

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF6471-SP

compare

(select up to 3 products from this page to compare)

page of 1

Popular Products	Company Information	Support	Stay Connected
Antibodies Secondary Antibodies Isotype Controls Proteins and Peptides ELISA Kits Sample Size New Products	About Us Careers Novus Guarantee Contact Us Our Team	Technical Support FAQs Help Finding Antibodies Protocols

Visit our other sites

©2024 Novus Biologicals, All Rights Reserved.